A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Part 1 and Part 2: Number of Participants with Adverse Events (AE)

AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.

Time frame: Approximately 3 years

Part 1 and Part 2: Number of Participants with AE by Severity

Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Severity scale ranges from Grade 1 (Mild) to Grade 4 (Life-threatening). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

Time frame: Approximately 3 years

Part 1 and Part 2: Number of Participants with Abnormal Vital Signs

Number of participants with abnormality in vital signs (temperature, pulse/heart rate, and blood pressure) will be reported.

Time frame: Approximately 3 years

Part 1 and Part 2: Number of Participants with Laboratory Abnormalities

Number of participants with laboratory abnormalities (serum chemistry, hematology, and coagulation, and disease-related laboratory abnormalities) will be reported.

Time frame: Approximately 3 years

Part 1 and Part 2: Number of Participants with Electrocardiogram (ECG) Abnormalities

Number of participants with electrocardiogram(ECG) abnormalities will be reported.

Time frame: Approximately 3 years

Part 1 and Part 2: Maximum Plasma Concentration (Cmax) of JNJ-64619178

Cmax is the maximum observed plasma concentration.

Time frame: Approximately 3 years

Part 1 and Part 2: Area Under the Plasma Concentration Versus Time Curve From Time Zero to End of Dosing Interval (AUCtau)

AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval.

Time frame: Approximately 3 years

Part 1 and Part 2: Minimum Plasma Concentration (Cmin)

Cmin is the minimum observed plasma concentration.

Time frame: Approximately 3 years

Part 1 and Part 2: Plasma Decay Half-Life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame: Approximately 3 years

Part 1 and Part 2: Volume of Distribution at Steady-State Influenced by the Fraction Absorbed (Vss/F)

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady state which is estimated by (D/AUC\[0-infinity\])\* (AUMC\[0-infinity\])/(AUC\[0-infinity\]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time. All these parameters will be assessed as influenced by the fraction absorbed.

Time frame: Approximately 3 years

Part 1 and Part 2: Apparent Total Systemic Clearance of Drug (CL/F) after Extravascular Administration

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame: Approximately 3 years

Part 1 and Part 2: Accumulation Index (RA)

Accumulation Index (RA) is calculated as AUC (0-24) value at steady state divided by AUC (0-24) value after first dose.

Time frame: Approximately 3 years

Part 1 and Part 2: Plasma Concentration of Symmetric Dimethyl-Arginine (SDMA)

Plasma concentration of symmetric dimethyl-arginine (SDMA) will be evaluated.

Time frame: Approximately 3 years

Part 1: Percentage of Participants with B cell non-Hodgkin lymphoma (NHL) Showing Overall Response of Partial Response (PR) or Better

Overall response rate (ORR) is defined as the percentage of participants who have a PR or better. Per Lugano classification, PR is defined as greater than or equal (\>=) 50 percent (%) decrease in size of target lesions.

Time frame: Approximately 3 years

Part 1: Percentage of Participants with Solid Tumors Showing Overall Response of PR or Better

Overall response rate (ORR) is defined as the percentage of participants who have a PR or better. PR criteria in solid tumors (RECIST) is \>= 30 percent (%) decrease in the sum of the diameters of all index lesions compared with baseline in 2 observations at least 4 weeks apart, in absence of new lesions or unequivocal progression of non-index lesions.

Time frame: Approximately 3 years

Part 1: Duration of Response

Duration of response (DOR) will be calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease (PD), as defined in the disease-specific response criteria, or death due to any cause, whichever occurs first. PD (per RECIST 1.1) defined as at least 20% increase in the sum of the longest diameters of index lesions or unequivocal progression of non-index lesions. Per Lugano classification, PD: target lesions larger; clear progression of non-target lesions; or new tumor lesions; new or recurrent bone marrow involvement; splenomegaly + 2 centimeter (cm) or +50%.

Time frame: Approximately 3 years

Part 1: Clinical Benefit Rate

Clinical benefit rate is defined as percentage of participants who have a complete response (CR), PR and sustained stable disease of 12 weeks or more. Sustained stable disease of 12 weeks or more is defined as participants with stable disease assessment maintained for about 12 weeks or longer from baseline. Per Lugano classification CR is defined as no detectable disease by computed tomography (CT) or positron emission tomography (PET)/CT scan. Evaluation criteria as per RECIST 1.1 for CR is defined as disappearance of all lesions in 2 consecutive observations not less than 4 weeks apart.

Time frame: Approximately 3 years

Part 2: Red Blood Cell (RBC) Transfusion Independence (TI) Rate

Percentage of participants with TI, defined as being without any transfusion during any consecutive 8 weeks (56 days) between the first dose of study drug and treatment discontinuation.

Time frame: Approximately 3 years

Part 2: Overall Improvement Rate

Overall improvement rate is defined as the percentage of participants achieving complete remission (bone marrow: less than or equal to (\<=)5% myeloblasts with normal maturation of all cell lines; Peripheral blood: hemoglobin \>=11 gram per deciliter (g/dL); platelets \>=100\*109/liter(L); neutrophils \>=1.0\*109/L; blasts, 0%), partial remission (All complete remission criteria if abnormal before treatment except: Bone marrow blasts decreased by \>=50% over pretreatment but still \>5% Cellularity and morphology not relevant), or hematologic improvement (HI) (Erythroid response \[pretreatment, \<11 g/dL\]; Platelet response (pretreatment, \<100\*10\^9/L); Neutrophil response (pretreatment, \<1\*10\^9/L); Progression or relapse after HI) according to modified International Working Group (IWG) criteria.

Time frame: Approximately 3 years